WASHINGTON: The United States has granted regulatory approval for the use of an Artificial Intelligence (AI)-powered ultrasound tool designed to enhance pregnancy care. This new technology, developed by Butterfly Network, promises to revolutionize the way medical professionals estimate gestational age and assess pregnancy health.
The US Food and Drug Administration FDA has authorized the AI ultrasound system which brings essential maternal healthcare services to remote communities through its advanced medical accessibility features. The device can determine pregnancy duration through a quick two-minute assessment process which provides users with accurate results. The device differs from standard ultrasound devices because it offers a user-friendly system which costs less than traditional equipment.
The AI-powered tool from Butterfly Network uses a single silicon chip to produce body imaging results, while standard ultrasound systems rely on costly piezoelectric crystals for image production. The company asserts that this approach not only reduces costs but also makes the technology more accessible in remote or resource-limited environments.
The AI system allows users to operate it without needing expertise in image capturing or medical measurement techniques. The system has learned from approximately 21 million ultrasound images which it received from various medical facilities and patient groups. The technology provides precise results for mid-term to late-term pregnancy assessments between 16 and 37 weeks’ gestation.
The FDA has shown back to artificial intelligence use in medical devices because it creates potential for healthcare improvements. AI-driven medical tools have the power to transform healthcare quality through their advanced capabilities.
